Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines Report
GBI Research, the leading business intelligence provider, has released its latest research, "Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines", which provides insights into the global biotech M&A and licensing strategies.
- (1888PressRelease) May 12, 2011 - Report Reserve announces addition of Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines Report. To access this report please visit http://www.reportreserve.com/reportdet.php?company=GBI%20Research&reportid=28810
GBI Research, the leading business intelligence provider, has released its latest research, "Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines", which provides insights into the global biotech M&A and licensing strategies. The report provides an in-depth analysis of the major M&A trends in the biotech industry along with the major drivers leading to an increased M&A activity in the current biotech industry. The report also delves into the M&A scenario in RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market. In addition, the report also analyzes the top 10 biotech companies with respect to the licensing agreement activities.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
Acquisition was the Predominant Strategy that Companies Followed in the Year 2009 and 2010
Acquisitions contributed to 71.7% of global M&A deals while mergers contributed to only 2.8%. Asset transaction contributed to and private equity was the second most adopted strategy by the companies. It accounted for 17% and 8.5% of the overall M&A deals in 2009 and 2010. Acquisition strategy was adopted by biotech companies to have high speed access to resources, avoid barriers of entry,expand their portfolio of products and to improve their asset valuation.
M&A Deals in Biotech by Type, Global, 2009 and 2010
Source: GBI Research
The Future of RNA Therapeutic R&D Pipeline Is Optimistic With More than Half of the Licensing Deals Took Place for Molecules, Which Are either In the Discovery or Development Stage
Out of the total 48 licensing deals studied between 2008 and 2009, 73% took place for molecules in the discovery and development stages; and 17% took place for molecules in the preclinical stage. 4% of the deals related to when the molecules were in either Phase II or Phase III clinical studies. The trend indicates that significantly more than half of the licensing deals took place for either discovery or development stage molecules indicating that the future of RNA therapeutic research and development will be prosperous for at least the next five years. Only 2% of the deals were signed between companies, when the RNA molecules were in phase I clinical development.
The Global Vaccines Market Has Been Highly Active In The M&A Landscape With Numerous Licensing And Co-Development Alliances
Approximately 81% of the deals in the global vaccines market comprised licensing and alliance deals, which reflects the strong need to partner for development of new vaccines.
Since, the global vaccines market is already highly consolidated there were fewer acquisition and mergers than alliances. However, one of the biggest deals in the vaccines industry was the acquisition of Wyeth by Pfizer for $68 billion in 2009.
Vaccines Market, Global, M&A Landscape by Deal Type, 2009
Source: GBI Research
Licensing and alliances accounted for the largest share of the global M&A and licensing deals landscape. There were 30 licensing deals and alliances in the global vaccines industry in 2009. The high number of licensing deals made is characteristic of the vaccines industry where technology and development platforms are highly fragmented. The development of a vaccine requires the licensing of various technologies, platforms and adjuvants to avoid legal problems in the future. This requires significant investment and thus makes the vaccines industry a largely unattractive segment for companies that do not have sufficient funds
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam